Real world treatment sequences and outcomes for metastatic renal cell carcinoma.

ABSTRACT:

Objectives

The treatment landscape for metastatic renal cell carcinoma changed a lot in the last few years. This study aimed to assess the treatment sequences and outcomes for metastatic renal cell carcinoma in a real-world setting.

Materials and methods

We enrolled patients with metastatic renal cell carcinomawho received first-line systemic treatment with tyrosin kinase inhibitors monotherapy, ipilimumab plus nivolumab, or pembrolizumab plus axitinibbetween January2009 and May 2023 on the database of TriNetX network. Overall survival, time on treatment and time to next treatment were evaluated using Kaplan-Meiermethod.

Results

Totally, 4183 received tyrosine kinase inhibitor monotherapy, 1555 received ipilimumab plus nivolumab, and 559 received axitinib plus pembrol

SUBMITTER: Lai GS 

PROVIDER: S-EPMC10664936 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature